Substitute for form 1449A/PTO	T	Parent and Trademark Chice; U.S. DEPARTMENT OF COMMERCE
INFORMATION DISCLOSURE	Application Number	10/520,839
O STATEMENT BY APPLICANT	Filing Date	January 7, 2005
/ 🍒	First Named Inventor	Robert J. Mathvink, et al:
APR 0 4 2006 (use assiring sheets as necessary)	Group Art Unit	·
N2 .0/	Examiner Name	
Sheet PADPUM I of 4	Attorney Docket Number	21139YP

U.S. PATENT DOCUMENTS								
Examiner Initials*	Cite No.	U.S. Patent Document Number	Kind Code (if known)	Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY			
VB	Α	6,699,871 B2		Edmondson et al.	03/02/2004			
VB	В	6,011,155		Villhauer	01/04/2000			
(7)	С	6,166,063		Villhauer	12/26/2000			
8	D	5,939,560		Jenkins et al.	08/17/1999			
M	E	6,303,661 B1		Demuth et al.	10/16/2001			
M	F	6,432,969 B1		Villhauer	08/13/2002			
W	G	4,386,090		Moinet et al	05/31/1983			
,								
		,						
		100						
**								
					<u> </u>			

FOREIGN PATENT DOCUMENTS						
Examiner Initials*	Cite No.	Office	Foreign Patent Document Number	Kind Code (if known)	Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY
W_2	Α	PCT	WO 03/082817 A2		MERCK & CO., INC.	10/09/2003
US	В	PCT	WO 03/000180 A2		MERCK & CO., INC.	01/03/2003
W	С	PCT	WO 03/000181 A2		MERCK & CO., INC.	01/03/2003
W	D	PCT	WO 03/000181 A3		MERCK & CO., INC.	01/03/2003
W)	E	PCT	WO 02/076450 A1		MERCK & CO., INC.	10/03/2002
M	F	PCT	WO 2004/007468 A1		MERCK & CO., INC.	01/22/2004
M	G	РСТ	WO 2004/032836 A2		MERCK & CO., INC.	04/22/2004
M	H	PCT	WO 2004/050022 A2		MERCK & CO., INC.	06/17/2004
W	I	PCT	WO 2004/058266 A1		MERCK & CO., INC.	07/15/2004
N	J	PCT	WO 2004/064778 A2		MERCK & CO., INC.	08/05/2004
Examin Signatu		V	Balasus	ano	Date Considered	10/29/06

Examiner Signature V. Pollosubscround Date Considered 16/20/56

*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

SEND TO: Commissioner for Patents, P. O. Box 1450, Alexandria, VA 22313-1450. Computer generated forth 1DS Forth? (IDS Folder), Merck & Co., Inc., 09/05/2003

Sut	estitute for form 1449A/PTO				COMPLET	•
r	NEORMATION	N DISC	SURE	Application Number	10/530,839	
	P ETATEMENT B	V A DDI	ICANT	Filing Date	January 7, 2005	
		'I AIII	CICANI	First Named Inventor	Robert J. Mathvink et al.	
Nº8	0 4 2005			Group Art Unit		
Prop	(use as maily she	ers as nec	essary)	Examiner Name		_
Sheet	2	of	4	Attorney Docket Number	21139YP	

			U.S. PATE	NT DOCUMENTS		
Examiner nitials*	Cite No.	U.S. Patent Docum		Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	
			(II signatur			
		•	- - 			
		•				
		- 1				
	·			•		
			-			
				·		

	FOREIGN PATENT DOCUMENTS						
Examiner	Examiner Cite		Foreign Patent Document		No- of Phoenics on Applicant	Date of Publication of	
Initials*	No.	Office	Number	Kind Code (if known)	Name of Patentee or Applicant of Cited Document	Cited Document MM-DD-YYYY	
∇D	K	PCT	WO 2004/069162 A2		MERCK & CO., INC.	08/19/2004	
M	L	PCT	WO 02/02560 A2		NOVO NORDISK A/S	01/10/2002	
W	M	PCT	WO 01/96295 A2		NOVARTIS AG	12/20/2001	
W	N	PCT	WO 01/96295 A3		NOVARTIS AG	12/20/2001	
M	0	PCT	WO 01/34594 A1		Guilford Pharmaceuticals, Inc.	05/17/2001	
M	P	PCT	WO 00/34241		NOVARTIS AG	06/15/2000	
W	Q	PCT	WO 98/19998 A2		NOVARTIS AG	05/14/1998	
	R	PCT	WO 98/19998 A3		NOVARTIS AG	05/14/1998	
W	S	PCT	WO 97/40832		Hansknoll-Institut Fur Naturstoff-Forschung E.V.	11/06/1997	
W	Т	PCT	WO 03/000180 A3		MERCK & CO., INC.	01/03/2003	

Examiner Signature Date Considered alasubeneni:

^{*}Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

SEND TO: Commissioner for Patents, P. O. Box 1450, Alexandria, VA 22313-1450. Computer generated form *IDS Form* (IDS Folder), Merck & Co., Inc., 09/05/2003

			Patent and Trademark Office; U.S DEPARTMENT OF COMMERCE	
	Substitute for form 1449A/PTO	· · · ·	COMPLET	_
	INFORMATION DISCLOSURE	Application Number	10/520,839	
1	STATEMENT BY APPLICANT	Filing Date	January 7, 2005	
Æ	PR 0 4 2005	First Named Inventor	Robert J. Mathvink, et al.	
\[\	(use as many sheets as necessary)	Group Art Unit		
R	Te musical State -	Examiner Name		
S	heet 3 of 4	Attorney Docket Number	21139YP	
				_

		Ū	.S. P/	ATENT DOCUMENTS		
Examiner Cite No.		U.S. Patent Document Kind Code ((f known)			Date of Publication of Cited Document MM-DD-YYYY	
			-			
				_		
		•				
			\vdash			
-				·		

	FOREIGN PATENT DOCUMENTS						
Examiner Initials*	Cite No.	Office	Foreign Patent Document Number	Kind Code	Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	
ΛM	บ	PCT	WO 02/02560	A3	NOVO NORDISK	01/10/2002	
M	V	PCT	WO 01/42262		AKZO NOBEL N.V.	06/14/2001	
18	w	PCT	WO 2004/043940		MERCK & CO., INC.	05/27/2004	
W	X	PCT	WO 2004/007468		MERCK & CO., INC.	01/22/2004	
M	Y	PCT	WO 2004/110436		MERCK & CO., INC.	12/23/2004	
M	Z	PCT	WO 2004/112701	A2	MERCK & CO., INC.	12/29/2004	
W	Zl	PCT	WO 2004/112701	A3	MERCK & CO., INC.	12/29/2004	
W	Z 2	PCT	WO 2005/011581	A2	MERCK & CO., INC.	02/10/2005	

Examiner Signature Date Considered 10/29/00

^{*}Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

SEND TO: Commissioner for Patents, P. O. Box 1450. Alexandria, VA 22313-1450. Computer generated form* IDS Form* (IDS Fother), Merck & Co., Inc., 09/05/2003

OMMERCE

		NON PATENT LITERATURE DOCUMENTS						
Examiner Initials*	Cite . No.	Include name of the author, title, date, page(s), volume-issue number(s) and place of publication.						
W	A	J. J. Holst, "Treatment of Type 2 Diabetes Mellitus with Agonists of the GLP-1 Receptor or DPP-IV Inhibitors", Expert Opin. Emerg. Drugs, Vol. 9(1) pp. 155-166, 2004.						
M	В	F. Deacon, et al., "Inhibitors of dipeptidyl peptidase IV: A Novel Approach for the Prevention and reatment of Type 2 Diabetes?", Expert Opin. Investig. Drugs, Vol. 13(9) pp. 1091-1102, 2004.						
W	С	K. Augustyns et al., "Dipeptidyl Peptidase IV Inhibitors as New Therapeutic Agents for the Treatment of Type 2 Diabetes", Expert Opin. Ther. Patents, Vol. 13(4), pp. 499-510, 2003.						
¥	D ·	Novartis AG: WO0034241, "Novel N-substituted-2-Cyanopyrrolidines as Potent Inhibitors of Dipeptidyl Peptidase IV in the Treatment of Non-Insulin-Dependent Diabetes Mellitus", Exp. Opin. Ther. Patents, Vol. 10(12), pp. 1937-1942, 2000.						
W	Е	O. J. Orucker, "Therapeutic potential of dipeptidyl peptidase IV inhibitors for the treatment of type 2 diabetes", Exp. Opin Invest. Drugs, Vol. 12, 2004, pages 87-100.						
3	F	T. P. Vahl & D. A. D'Alessio, "Gut peptides in the treatment of diabetes mellitus" Exp. Opin. Invest. Drugs, Vol. 13, 2004, pages 177-188.						
3	G	L. B. Knudsen, "Glucagon-like peptide-1: The Basis of a New Class of Treatment for Type 2 Diabetes", J. Med. Chem, Vol. 47, 2004, pages 4128-4134.						
CY	Н	Ann E. Weber, "Dipeptidyl Peptidase IV Inhibitors for the Treatment of Diabetes", J. Med. Chem, Vol. 47, 2004, pages 4135-4141.						
M	I	J. J. Holst and C. F. Deacon, "Glucagon-like peptide 1 and inhibitors of dipeptidyl peptidase IV in the treatment of type 2 diabetes mellitus", Curr. Opin Pharmacology, Vol. 4, 2004, pages 589-596.						
W	J	C. F. Deacon, "Perspectives in Diabetes - Therapeutic Strategies Based on Glucagon-Like Peptide 1", Diabetes, Vol. 53, Sept. 2004, pages 2181-2189.						

Examiner Signature	Baleserranen	Date Considered	10/	29186